These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 33509222)

  • 1. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
    Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
    Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
    Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
    Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
    Wu R; Wu C; Zhu B; Li J; Zhao W
    Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
    [No Abstract]   [Full Text] [Related]  

  • 5. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a prognostic model of luteolin for endometrial carcinoma.
    Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
    Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
    Liu J; Ji C; Wang Y; Zhang C; Zhu H
    Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
    Zhou C; Li C; Yan F; Zheng Y
    Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
    Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
    Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
    [No Abstract]   [Full Text] [Related]  

  • 13. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
    Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
    Front Oncol; 2021; 11():766947. PubMed ID: 34868993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Expression of Pyroptosis-Related Gene May Influence the Occurrence, Development, and Prognosis of Uterine Corpus Endometrial Carcinoma.
    Huang X; Li Y; Li J; Yang X; Xiao J; Xu F
    Front Oncol; 2022; 12():885114. PubMed ID: 35574367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
    Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
    Front Oncol; 2022; 12():923641. PubMed ID: 35719911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.
    Liu ZS; Jing CL
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Expression of Gamma-Glutamyl Hydrolase Is Associated With Poor Prognosis and Altered Immune Signature in Uterine Corpus Endometrial Carcinoma.
    Yu C; Qi H; Zhang Y; Zhao W; Wu G
    Front Genet; 2021; 12():764194. PubMed ID: 35082830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
    Lu X; Jing L; Liu S; Wang H; Chen B
    Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.